Thursday, October 8, 2026

India’s bioeconomy valuation surged 18 pc to $195 bn in 2025: Report

Date:

India’s bioeconomy valuation surged from $166 billion in 2024 to $195 billion in 2025, reflecting strong growth across multiple biotechnology-driven industries.The BioEconomy is no longer defined solely by BioPharmaceutical or BioIndustrial. It now spans a broader industrial ecosystem where biofuels, enzyme solutions, digital biology platforms, contract research, biologics manufacturing, and agricultural biological inputs collectively contribute to national economic output.

The report, ’India Bioeconomy Report 2026’, was published by the Biotechnology Industry Research Assistance Council (BIRAC), a public sector undertaking (PSU) that aims to strengthen and empower the emerging biotech enterprise.

The expansion in the bioeconomy valuation has been led by four factors: 20% blending of ethanol in petrol, which reduced petrol imports; the consumption of the GLP-1 class of drugs; the opening of new Global Capability Centers (GCCs), which employ over 300,000 Indian professionals; and the usage of biosolutions using enzymes and microbes in the various industrial sectors.”These four emerging trends and new product areas, along with the other traditional biotechnology segments, have led to India’s BioEconomy adding $29.6 billion in 2025. This 18% growth is the highest witnessed in the last few years,” said the report.BIRAC has played a crucial role in the expansion of bioeconomy by seeding innovations in biopharma, med-tech, agri-biotech, health-tech, industrial biotech, and clean-tech through programmes spanning grant funding, equity support, mentoring, and partnerships.”In just 14 years, BIRAC has helped transform Indian biotechnology from a small, fragmented sector into a vibrant innovation-driven ecosystem,” Rajesh S Gokhale, secretary of the Department of Biotechnology, said.Gokhale also noted that by catalysing ₹7,000 crore in total investment across lakhs of startups, entrepreneurs, and companies, BIRAC supported the development of more than 900 products and over 35,000 high-skilled jobs.Jitendra Kumar, managing director of BIRAC, said in a statement, ”Our ambition is bold: to grow India’s bioeconomy to $300 billion by 2030 and $1 trillion by 2047. With strong foundations in vaccines, biopharma, agribiotech, bioindustrial manufacturing, and clean energy, India is steadily emerging as a top global biotech innovation hub.”

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

RBI Bulletin says Indian economy remains resilient but global risks are rising

India’s economy remains resilient despite a worsening global backdrop,...

12 years of Make in India: What worked, what’s unfinished and what comes next

India has made visible gains in manufacturing over the...

Why India did not sign an FTA with China, according to Piyush Goyal

India had signed trade agreements with economies such as...

EU regulations could push up costs and hurt European businesses, Piyush Goyal says

Commerce and Industry Minister Piyush Goyal has warned that...